|
Fig. 9. Gαi/o acts downstream of Xmsr. (A) ControlMO (20 ng)-injected embryo at stage 45. (B) XmsrMO (mMO) (20 ng)-injected embryo at stage 45. (C) Embryos coinjected pCS2-Xmsr 5m DNA (50 pg) (C), pCS2-EGFP DNA (50 pg) (D), pCS2-Gαi2QL (10 pg) (E), pCS2-Gαs short (10 pg) (F), pCS2-GαqQL (10 pg) (G), and pCS2-Gα12QL (10 pg) (H) with XmsrMO at stage 45. The embryos shown in the left of panels C and E are the embryos with normal phenotypes and the embryos shown in right of the panels are the embryos with edema phenotypes. The numbers shown in the bottom right of panels A indicate the percentage of edematous embryos, and the numbers shown in the bottom left of the panels indicate the percentage of normal embryos. (I) cTnI expression in controlMO (20 ng)- injected embryo. (J) cTnI expression in XmsrMO (mMO) (20 ng)-injected embryo. (K) cTnI expression in embryos coinjected with pCS2-Xmsr 5m DNA (50 pg) (K), pCS2-Gαi2QL (10 pg) (L), pCS2-Gαs short (10 pg) (M), pCS2-GαqQL (10 pg) (N), and pCS2-Gα12QL (10 pg) (O) with XmsrMO. The embryos shown in the left of panels J are the embryos with normal cTnI expression, and the embryos shown in the right of the panels are the embryos with reduced cTnI expression. The numbers shown at the bottom right of panels I indicate the percentage of the embryos with reduced cTnI expression, and the numbers shown at the bottom left of the panels indicate the percentage of the embryos with normal cTnI expression. (P, Q) Graphs summarizing the results above. |